Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Promising findings from a study of a two-drug injectable treatment given every four weeks.
The company has released new data from a trial of injectable cabotegravir and Edurant given every four or eight weeks.
ViiV Healthcare has reported promising one-year findings from a study of a two-drug injectable treatment given every four weeks.
Researchers presented 100-week data on a trial of the antiretroviral (ARV) regimen at the international AIDS conference.
In a recent study, Edurant was better tolerated and less toxic and led to fewer discontinuations.
Juluca is a single-tablet regimen for HIV.
HIV-positive members of a recent study saw many upsides to getting injections of meds only every four or eight weeks.
The single-tablet regimen contains ViiV’s Tivicay (dolutegravir) and Janssen’s Edurant (rilpivirine).
ViiV Healthcare has applied to the FDA for approval of the first two-drug antiretroviral (ARV) regimen to treat HIV.
Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.
The combo of Tivicay (dolutegravir) and Edurant (rilpivirine) showed comparable efficacy to three- and four-drug regimens in major trials.
In a small study, the drop in seminal viral load in men who started treatment with PIs lagged behind that of men going on other HIV meds.
Two large studies have found that the two-drug combination of Tivicay and Edurant works as well as standard three- or four-ARV regimens.
Two large trials switched participants from three- or four-drug combos to a regimen of Tivicay (dolutegravir) and Edurant (rilpivirine).
A long-acting injectable HIV regimen dosed every four weeks is slated to advance to Phase III trials in late 2016.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.